Phase 3 Readouts — Q3 2026
Phase 3 clinical trial readouts are pivotal moments for biotech companies. These large-scale trials (1,000-5,000+ patients) determine whether a drug has enough evidence of efficacy and safety to seek FDA approval.
57 phase 3 readouts in Q3 2026. Updated .
Phase 3 Topline: A Randomized, Multicenter, Double-blind, Parallel-group, Active-control Study of the Efficacy and Sa
Travere Therapeutics, Inc. (TVTX)
Phase 3 Topline: A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Ef
ELI LILLY & Co (LLY)
Phase 3 Topline: SELVA: A Multicenter, Phase 3 Baseline-Controlled Study Evaluating the Safety and Efficacy of QTORIN
PALVELLA THERAPEUTICS, INC. (PVLA)
Phase 3 Topline: Does Prophylactic Local Tobramycin Injection Lower Open Fracture Infection Rates?
UNITED THERAPEUTICS Corp (UTHR)
Phase 3 Topline: A Randomized, Multi-center, Phase 3 Study of Nivolumab in Combination With Ipilimumab Compared to So
BRISTOL MYERS SQUIBB CO (BMY)
Phase 3 Topline: Efficacy and Safety of FMXIN002 Epinephrine Powder Nasal Spray for the Treatment of Acute Allergic R
Nasus Pharma Ltd (NSRX)
Phase 3 Topline: Efficacy and Safety of Co-administered Cagrilintide and Semaglutide (CagriSema) 1.0 mg/1.0 mg s.c. O
Novo Nordisk A/S (NVO)
Phase 3 Topline: A Multicenter, Double-blind, Randomized Withdrawal Extension Study of Subcutaneous Secukinumab to De
Novartis AG (NVS)
Phase 3 Topline: A Phase 3B, Multicenter, Randomized, Double-blind, Placebo-controlled Study Evaluating the Efficacy
Crinetics Pharmaceuticals, Inc. (CRNX)
Phase 3 Topline: A MASTER PHASE 1/2/3 PROTOCOL TO INVESTIGATE THE SAFETY, TOLERABILITY, AND IMMUNOGENICITY OF VARIANT
BioNTech SE (BNTX)
Phase 3 Topline: A Multicenter, Randomized, Double-blind, Placebo-controlled Phase IIb/III Study to Assess the Effica
TG THERAPEUTICS, INC. (TGTX)
Phase 3 Topline: A Single Center, Open Label, Expanded Access Study of QRX003 Lotion in Subjects With Netherton Syndr
Quoin Pharmaceuticals, Ltd. (QNRX)
Phase 3 Topline: A Phase 3 Study to Evaluate the Immunogenicity and Safety of mRNA-1345, an mRNA Vaccine Targeting Re
Moderna, Inc. (MRNA)
Phase 3 Topline: A Randomized, Open Label, Phase III Trial to Evaluate the Efficacy and Safety of Palbociclib + Anti-
ENANTA PHARMACEUTICALS INC (ENTA)
Phase 3 Topline: A PHASE 3 PROTOCOL TO INVESTIGATE THE SAFETY, TOLERABILITY, AND IMMUNOGENICITY OF A BNT162b2 (LP.8.1
BioNTech SE (BNTX)
Phase 3 Topline: A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED CLINICAL STUDY EVALUATING THE SAFETY, TOLERA
BioNTech SE (BNTX)
Phase 3 Topline: A Phase 3, Randomized, Double-Blind Study to Evaluate the Safety, Serum Virus Neutralizing Antibody
Invivyd, Inc. (IVVD)
Phase 3 Topline: A Phase 3, Randomized, Triple-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of
Invivyd, Inc. (IVVD)
Phase 3 Topline: A Randomized, Open-Label, Active-Controlled Study Evaluating the Efficacy of Three Times Weekly Vada
Akebia Therapeutics, Inc. (AKBA)
Phase 3 Topline: A Phase III, Long-Term, Randomized, Double-blind, Placebo-controlled Trial of Troriluzole in Adult P
West Pharmaceutical Services Inc. (WST)
Phase 3 Topline: A Multicenter, Randomized, Double Blind, Vehicle-controlled, Phase 3 Efficacy and Safety Study of Pa
Sol-Gel Technologies Ltd. (SLGL)
Phase 3 Topline: A Multicenter, Double-masked, Randomized Study to Compare the Efficacy and Safety of the ABBV-444 Te
AbbVie Inc. (ABBV)
Phase 3 Topline: A Phase 3 Global, Double-Blind, Randomized, Placebo-Controlled Study to Evaluate the Efficacy and Sa
IONIS PHARMACEUTICALS INC (IONS)
Phase 3 Topline: Donepezil Use Versus Non-drug Approach in Treatment of Newly Diagnosed Alzheimer's Disease : a Multi
Crinetics Pharmaceuticals, Inc. (CRNX)
Phase 3 Topline: A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy
BIOMARIN PHARMACEUTICAL INC (BMRN)
Phase 3 Topline: A Phase 3, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of
Pharvaris N.V. (PHVS)
Phase 3 Topline: A Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter Study to Evaluate the Ef
LEXICON PHARMACEUTICALS, INC. (LXRX)
Phase 3 Topline: A Study Investigating Clinical Comparability of Two Formulations of Oral Semaglutide in Japanese Par
Novo Nordisk A/S (NVO)
Phase 3 Topline: A Phase III, Randomized, Open-Label, Multicenter Study of Lurbinectedin in Combination With Atezoliz
Jazz Pharmaceuticals plc (JAZZ)
Phase 3 Topline: A Phase III Study to Assess the Efficacy and Safety of NEXIUM for Maintenance of Healing of Erosive
ASTRAZENECA PLC (AZN)
Phase 3 Topline: A Randomized, Open-label, Multi-center Phase III Study of Durvalumab and Tremelimumab as First-line
ASTRAZENECA PLC (AZN)
Phase 3 Topline: Comparison of Efficacy of Tranexamic Acid Versus Vasopressin in Blood Loss Among Placenta Previa Pat
ENANTA PHARMACEUTICALS INC (ENTA)
Phase 3 Topline: A Phase 3, Randomized, Double-blind, Placebo-controlled, Parallel-group Study to Investigate the Eff
Sanofi (SNY)
Phase 3 Topline: A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study With An Open Label Safety
Zenas BioPharma, Inc. (ZBIO)
Phase 3 Topline: A Phase III, Randomized, Double-blind, Placebo-controlled, Multicenter Study of Transarterial Chemoe
ASTRAZENECA PLC (AZN)
Phase 3 Topline: A Phase 3, Randomized, Double-Blind, 52-Week Study of OLZ/SAM vs Olanzapine to Evaluate Weight Gain
Alkermes plc. (ALKS)
Phase 3 Topline: A Phase 3, Multi-Center, Randomized, Double-Blind Trial to Evaluate the Efficacy and Safety of Afica
CYTOKINETICS INC (CYTK)
Phase 3 Topline: A Phase III, Placebo-Controlled, Randomized, Double-Blind Trial of Oral Doses of CYB003 to Assess Co
CYBIN INC. (HELP)
Phase 3 Topline: A Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Multi-dose Study to Evaluate the Eff
Veradermics Incorporated (MANE)
Phase 3 Topline: A 12-Week, Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study to Assess the Safety and Effi
ARDELYX, INC. (ARDX)
Phase 3 Topline: Double-blind, Placebo-controlled, Phase 3 Study to Evaluate the Efficacy and Safety of Plozsiran in
ARROWHEAD PHARMACEUTICALS, INC. (ARWR)
Phase 3 Topline: Opiate-sparing Post-operative Pain Control in Septorhinoplasty: A Prospective Randomized, Double Bli
UNITED THERAPEUTICS Corp (UTHR)
Phase 3 Topline: Open-Label, Randomized Study With a Tocilizumab Reference Arm to Evaluate Safety, Efficacy and Pharm
ELI LILLY & Co (LLY)
Phase 3 Topline: Double-blind, Placebo-controlled, Phase 3 Study to Evaluate the Efficacy and Safety of Plozasiran in
ARROWHEAD PHARMACEUTICALS, INC. (ARWR)
Phase 3 Topline: Targeted Intra-arterial Gemcitabine vs. Continuation of IV Gemcitabine Plus Nab-Paclitaxel Following
RenovoRx, Inc. (RNXT)
Phase 3 Topline: A Phase 3, Single-arm, Multicenter Study to Evaluate the Efficacy and Safety of UGN-103, a Novel For
UroGen Pharma Ltd. (URGN)
Phase 3 Topline: A Phase IIIb, Single Arm, Open-label, Multicentre Study of Durvalumab in Combination With Chemothera
ASTRAZENECA PLC (AZN)
Phase 3 Topline: A Phase 3, Randomized, Efficacy and Safety Study of Enzalutamide Plus Leuprolide, Enzalutamide Monot
PFIZER INC (PFE)
Phase 3 Topline: A 4-Week, Double-Blind, Placebo-Controlled, Parallel-Group, Efficacy and Safety Trial of Fluticasone
Teva Pharmaceutical Industries Limited (TEVA)
Phase 3 Topline: A Randomized, Controlled, Open Label, Phase III Study Evaluating the Efficacy and Safety of JDQ443 V
Novartis AG (NVS)
Phase 3 Topline: A Phase 3, Modified Double-blind, Multi-center Study of the Immunogenicity and Safety of an Investig
Sanofi (SNY)
Phase 3 Topline: A Phase 3 Randomized, Double-blind, Multicenter, Global Study of Monalizumab or Placebo in Combinati
ASTRAZENECA PLC (AZN)
Phase 3 Topline: A PHASE 1 STUDY TO ASSESS THE SAFETY AND EFFICACY OF OCU410ST FOR STARGARDT DISEASE AND PHASE 2/3 PI
Ocugen, Inc. (OCGN)
Phase 3 Topline: An Open-label, Single-arm Study to Evaluate the Pharmacokinetics and Safety of Subcutaneous Soneloki
MoonLake Immunotherapeutics (MLTX)
Phase 3 Topline: PSMAfore: A Phase III, Open-label, Multi-Center, Randomized Study Comparing 177Lu-PSMA-617 vs. a Cha
Novartis AG (NVS)
Phase 3 Topline: A Phase IIIb Single Arm, Open-label, Multicentre Study of Durvalumab and Tremelimumab as First Line
ASTRAZENECA PLC (AZN)
Phase 3 Topline: An Open-label, Uncontrolled Study to Evaluate the Pharmacokinetics, Pharmacodynamics, Safety, and Ac
ARGENX SE (ARGX)